Literature DB >> 164279

The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.

E Hurwitz, R Levy, R Maron, M Wilchek, R Arnon, M Sela.   

Abstract

Daunomycin and adriamycin, two potent cancer chemotherapeutic agents, were linked to immunoglobulins, making use of various covalent cross-linking methods. The most suitable method for binding of the drugs to the antibodies, which retained both antibody and drug activity, was periodate oxidation of the drug, followed by the linking of the oxidized drug to the immunoglobulin and subsequent reduction of the product with sodium borohydride. The activity of the drug-antibody conjugates was tested in vitro on tumor and normal cell cultures and was found to be similar to that of the free drug. A significant amount of antibody activity was retained, as found both with anti-bovine serum albumin antibodies, assayed by chemically modified bacteriophage, and with anti-mouse tumor antibodies, assayed by C'-dependent cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 164279

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.

Authors:  Vishwesh Patil; Keyur Gada; Rajiv Panwar; Alexandra Varvarigou; Stan Majewski; Andrew Weisenberger; Craig Ferris; Yared Tekabe; Ban-An Khaw
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05       Impact factor: 9.236

2.  Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

Authors:  A Nagy; A V Schally; P Armatis; K Szepeshazi; G Halmos; M Kovacs; M Zarandi; K Groot; M Miyazaki; A Jungwirth; J Horvath
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  My life with affinity.

Authors:  Meir Wilchek
Journal:  Protein Sci       Date:  2004-11       Impact factor: 6.725

4.  Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole.

Authors:  E E Hassan; R C Parish; J M Gallo
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

5.  The effect of anti-AFP-F(ab)'2 and adriamycin conjugate on transplantable tumors in mice.

Authors:  W X Tang; P L Li; W Y Zhang; S B Li
Journal:  J Tongji Med Univ       Date:  1991

Review 6.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 7.  Analytical methods for physicochemical characterization of antibody drug conjugates.

Authors:  Aditya Wakankar; Yan Chen; Yatin Gokarn; Fredric S Jacobson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

8.  Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines.

Authors:  K Ohkawa; N Hibi; Y Tsukada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 9.  Immunoconjugates: applications in targeted drug delivery for cancer therapy.

Authors:  B P Ram; P Tyle
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

10.  A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Authors:  A Trouet; M Masquelier; R Baurain; D Deprez-De Campeneere
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.